{"id":"NCT00254202","sponsor":"Vanda Pharmaceuticals","briefTitle":"Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia","officialTitle":"A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Iloperidone in Schizophrenic Patients in Acute Exacerbation Followed by a Long-term Treatment Phase.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-11-18","primaryCompletion":"2006-09-26","completion":"2007-03-21","firstPosted":"2005-11-15","resultsPosted":"2024-12-13","lastUpdate":"2024-12-13"},"enrollment":593,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Iloperidone","otherNames":["FanaptÂ®","VYV-683"]},{"type":"DRUG","name":"Ziprasidone","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Iloperidone","type":"EXPERIMENTAL"},{"label":"Ziprasidone","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine the safety and efficacy of iloperidone compared to placebo and an active comparator in the treatment of patients with schizophrenia in acute exacerbation.","primaryOutcome":{"measure":"Change From Baseline in Positive and Negative Symptom Scale Total (PANSS-T) Score","timeFrame":"4 weeks","effectByArm":[{"arm":"Iloperidone","deltaMin":-12,"sd":1.03},{"arm":"Ziprasidone","deltaMin":-12.3,"sd":1.44},{"arm":"Placebo","deltaMin":-7.1,"sd":1.48}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":42,"countries":["United States","India"]},"refs":{"pmids":["19573479"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":300},"commonTop":["Headache","Sedation","Dizziness","Nausea","Dyspepsia"]}}